Research Analysts Set Expectations for Liquidia Q4 Earnings

Liquidia Corporation (NASDAQ:LQDA) – Research analysts at Lifesci Capital cut their Q4 2026 earnings per share (EPS) estimates for shares of Liquidia in a report released on Tuesday, May 12th. Lifesci Capital analyst G. Maini now forecasts that the company will earn $0.90 per share for the quarter, down from their previous estimate of $0.95. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Liquidia’s current full-year earnings is $2.14 per share.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 81.61% and a net margin of 7.74%.Liquidia’s revenue for the quarter was up 4187.1% compared to the same quarter last year.

Other equities analysts have also issued reports about the company. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Oppenheimer increased their price objective on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research report on Thursday, March 12th. Needham & Company LLC increased their price objective on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Finally, Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

Liquidia Price Performance

Shares of Liquidia stock opened at $56.60 on Wednesday. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97. The firm has a market capitalization of $5.03 billion, a PE ratio of 404.31 and a beta of 0.41. The business’s 50-day moving average price is $38.17 and its 200-day moving average price is $35.29. Liquidia has a 12 month low of $11.85 and a 12 month high of $57.00.

Insider Buying and Selling

In related news, CEO Roger Jeffs sold 32,744 shares of the firm’s stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $38.37, for a total transaction of $1,256,387.28. Following the transaction, the chief executive officer directly owned 1,137,599 shares in the company, valued at $43,649,673.63. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Stephen M. Bloch sold 62,550 shares of the firm’s stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $35.94, for a total value of $2,248,047.00. Following the transaction, the director owned 2,188,935 shares in the company, valued at approximately $78,670,323.90. The trade was a 2.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 653,820 shares of company stock worth $25,838,508 in the last ninety days. 25.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Liquidia

Several institutional investors and hedge funds have recently bought and sold shares of LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after buying an additional 1,700 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Liquidia by 10.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after buying an additional 82,955 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Liquidia by 15.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after buying an additional 16,022 shares during the period. Creative Planning lifted its holdings in Liquidia by 40.7% in the 2nd quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after buying an additional 7,765 shares during the period. Finally, Legal & General Group Plc lifted its holdings in Liquidia by 13.4% in the 2nd quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after buying an additional 11,111 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported a major Q1 beat, with EPS of $0.52 versus $0.41 expected and revenue of $132.87 million versus $119.44 million expected, reinforcing the company’s rapid commercial growth and improving profitability. Earnings report
• Positive Sentiment: Management said YUTREPIA net product sales rose 44% sequentially and projected at least $1 billion in net revenue by 2027, signaling strong launch momentum and a long growth runway. Seeking Alpha article
• Positive Sentiment: Needham raised its price target to $70 and BTIG lifted its target to $59, both keeping bullish ratings in place, which suggests Wall Street sees more upside after the earnings beat. Needham price target note
• Positive Sentiment: Zacks added Liquidia to its Strong Buy list, adding another sentiment boost following the earnings release. Zacks Strong Buy list
• Neutral Sentiment: CEO Roger Jeffs sold 25,000 shares in a pre-arranged 10b5-1 plan; while this is worth noting, it appears routine and relatively small versus his remaining stake. SEC filing
• Negative Sentiment: One recent downgrade argued that YUTREPIA’s launch momentum may be approaching a ceiling, raising questions about how much additional market-share expansion remains. Seeking Alpha downgrade

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).